4
Changes in Ownership
Celldex Therapeutics, Inc. Filed Acc 0001415889-24-017363
SVP AND CFO sold 17,172 shares at $35.42 ($608,315)
- SVP AND CFO acquired 20,169 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Martin Samuel Bates SVP AND CFO | 2024-06-14 | Option exercise | +3,201 | $9.02 | $28,862 | 28,329 | D |
| Martin Samuel Bates SVP AND CFO | 2024-06-14 | Option exercise | +16,968 | $10.38 | $176,128 | 45,297 | D |
| Martin Samuel Bates SVP AND CFO | 2024-06-14 | Sale | −17,172 | $35.42 | $608,315 | 28,125 | D |
| Derivatives | |||||||
| Martin Samuel Bates SVP AND CFO | 2024-06-14 | Option exercise · Incentive Stock Option (Right to Buy) | −3,201 | 0 | D | ||
| Martin Samuel Bates SVP AND CFO | 2024-06-14 | Option exercise · Incentive Stock Option (Right to Buy) | −16,968 | 63,632 | D | ||
| Open-market sales · 17,172 sh · avg $35.42 · $608,315 | |||||||
Loading xslF345X05/form4-06182024_080610.xml…